Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation

Kanqiu Jiang,* Mingjing Shen,* Weihua Xu Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou Shi, Jiangsu Sheng, People’s Republic of China *These authors contributed equally to this work Purpose: In this study, a novel arginine, glycine, a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiang K, Shen M, Xu W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	RGD Paclitaxel Curcumin liposome Cell uptake Cytotoxicity study In vivo anti-tumor study Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/dbb63c5e22f3429ca2ab4669dba9b41f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dbb63c5e22f3429ca2ab4669dba9b41f
record_format	dspace
spelling	oai:doaj.org-article:dbb63c5e22f3429ca2ab4669dba9b41f2021-12-02T04:23:40ZArginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation1178-2013https://doaj.org/article/dbb63c5e22f3429ca2ab4669dba9b41f2018-04-01T00:00:00Zhttps://www.dovepress.com/arginine-glycine-aspartic-acid-peptide-modified-paclitaxel-and-curcumi-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Kanqiu Jiang,* Mingjing Shen,* Weihua Xu Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou Shi, Jiangsu Sheng, People’s Republic of China *These authors contributed equally to this work Purpose: In this study, a novel arginine, glycine, aspartic acid peptide (RGD)-modified paclitaxel and curcumin co-loaded liposomes were developed to evaluate their antitumor activity in vitro and in vivo. Materials and methods: Co-loaded liposomes were prepared using the solvent evaporation method. The particles had spherical shapes under electron microscopy with sizes <130 nm. Results: By comparison with the free drug, RGD-modified paclitaxel and curcumin co-loaded liposomes and paclitaxel and curcumin co-loaded liposomes have sustained-release properties in vitro. In vivo, there was no significant difference in pharmacokinetic parameters between the RGD-modified paclitaxel and curcumin co-loaded liposomes and paclitaxel and curcumin co-loaded liposomes. A strong green fluorescence was observed in the cytoplasmic region after incubation of RGD-modified paclitaxel and curcumin co-loaded liposomes for 2 h. RGD-modified paclitaxel and curcumin co-loaded liposomes showed a superior antiproliferative effect on A549 cells with a possible mechanism that suppressed the multidrug resistance phenomenon and exhibited a clear synergistic effect. Conclusion: The results indicate that RGD-modified paclitaxel and curcumin co-loaded liposomes had a better antitumor effect in vivo than the non-modified LPs. These results indicate that RGD-modified co-loaded liposomes are a promising candidate for antitumor drug delivery. Keywords: arginine, glycine, aspartic acid peptide, paclitaxel, curcumin, liposome, cell uptake, cytotoxicity study, in vivo anti-tumor studyJiang KShen MXu WDove Medical PressarticleRGDPaclitaxelCurcuminliposomeCell uptakeCytotoxicity studyIn vivo anti-tumor studyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 2561-2569 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	RGD Paclitaxel Curcumin liposome Cell uptake Cytotoxicity study In vivo anti-tumor study Medicine (General) R5-920
spellingShingle	RGD Paclitaxel Curcumin liposome Cell uptake Cytotoxicity study In vivo anti-tumor study Medicine (General) R5-920 Jiang K Shen M Xu W Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation
description	Kanqiu Jiang,* Mingjing Shen,* Weihua Xu Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou Shi, Jiangsu Sheng, People’s Republic of China *These authors contributed equally to this work Purpose: In this study, a novel arginine, glycine, aspartic acid peptide (RGD)-modified paclitaxel and curcumin co-loaded liposomes were developed to evaluate their antitumor activity in vitro and in vivo. Materials and methods: Co-loaded liposomes were prepared using the solvent evaporation method. The particles had spherical shapes under electron microscopy with sizes <130 nm. Results: By comparison with the free drug, RGD-modified paclitaxel and curcumin co-loaded liposomes and paclitaxel and curcumin co-loaded liposomes have sustained-release properties in vitro. In vivo, there was no significant difference in pharmacokinetic parameters between the RGD-modified paclitaxel and curcumin co-loaded liposomes and paclitaxel and curcumin co-loaded liposomes. A strong green fluorescence was observed in the cytoplasmic region after incubation of RGD-modified paclitaxel and curcumin co-loaded liposomes for 2 h. RGD-modified paclitaxel and curcumin co-loaded liposomes showed a superior antiproliferative effect on A549 cells with a possible mechanism that suppressed the multidrug resistance phenomenon and exhibited a clear synergistic effect. Conclusion: The results indicate that RGD-modified paclitaxel and curcumin co-loaded liposomes had a better antitumor effect in vivo than the non-modified LPs. These results indicate that RGD-modified co-loaded liposomes are a promising candidate for antitumor drug delivery. Keywords: arginine, glycine, aspartic acid peptide, paclitaxel, curcumin, liposome, cell uptake, cytotoxicity study, in vivo anti-tumor study
format	article
author	Jiang K Shen M Xu W
author_facet	Jiang K Shen M Xu W
author_sort	Jiang K
title	Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation
title_short	Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation
title_full	Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation
title_fullStr	Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation
title_full_unstemmed	Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation
title_sort	arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/dbb63c5e22f3429ca2ab4669dba9b41f
work_keys_str_mv	AT jiangk arginineglycineasparticacidpeptidemodifiedpaclitaxelandcurcumincoloadedliposomeforthetreatmentoflungcancerinvitrovivoevaluation AT shenm arginineglycineasparticacidpeptidemodifiedpaclitaxelandcurcumincoloadedliposomeforthetreatmentoflungcancerinvitrovivoevaluation AT xuw arginineglycineasparticacidpeptidemodifiedpaclitaxelandcurcumincoloadedliposomeforthetreatmentoflungcancerinvitrovivoevaluation
_version_	1718401277649485824

Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation

Ejemplares similares